Factors Affecting Higher Readmission Rates and Costs in Pediatric Patients With Hirschsprung Disease

Anthony R Pecoraro1, Chelsea E Hunter2, William E Bennett2

  • 1Department of Surgery, Division of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, Indianapolis.

Insights

Hirschsprung disease patients with surgical complications or genetic defects face longer hospital stays and higher costs. Identifying these patient factors can help reduce readmissions and healthcare expenses.

Area of Science:

  • Pediatric Surgery
  • Gastroenterology
  • Health Services Research

Background:

  • Hirschsprung disease is a rare congenital gastrointestinal disorder requiring surgical treatment.
  • Readmissions and complications are known concerns for Hirschsprung disease patients post-surgery.
  • Factors influencing prolonged hospital stays, increased costs, and readmissions after pull-through surgery require identification.

Purpose of the Study:

  • To identify patient-level factors associated with prolonged hospital stay after pull-through operation for Hirschsprung disease.
  • To determine factors linked to increased healthcare costs during the pull-through operation.
  • To assess patient-level predictors of all-cause inpatient readmission following surgery for Hirschsprung disease.

Main Methods:

  • Utilized data from the Pediatric Health Information System database (2004-2019).
  • Analyzed a cohort of 3345 patients who underwent a pull-through operation for Hirschsprung disease.
  • Performed multivariable regression analyses to identify key outcome variables: postoperative length of stay (LOS) and adjusted charges.

Main Results:

  • Surgical complications, congenital/genetic defects, and neurologic/neuromuscular defects significantly increased postoperative LOS.
  • Black patients experienced increased LOS.
  • Admittance to NICU and ICU during the index hospitalization correlated with higher costs (approx. $75,000 and $57,000 increases, respectively).
  • Surgical complications, comorbid congenital/genetic defects, and mechanical ventilation need were associated with higher odds of inpatient readmission.

Conclusions:

  • Management of Hirschsprung disease is complex and longitudinal.
  • Identifying key patient metrics can guide targeted care and education strategies.
  • Minimizing readmissions and excessive hospital charges is crucial for effective Hirschsprung disease management.
Abstract

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
988
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
159